INTRODUCTION: Fibroblast growth factor (FGF-23) is a novel phosphaturic factor. Current data suggest that serum phosphate, dietary phosphate and 1,25 dihydroxyvitamin D regulate circulating FGF-23 levels in vivo. We examined if hypogonadism-induced increases in serum phosphate are associated with increases in circulating FGF-23 in healthy men in the absence of dietary manipulation. MATERIALS AND METHODS: 25 healthy men were administered goserelin acetate (GnRH analog) 3.6 mg subcutaneously every 4 weeks for 12 weeks to induce acute testosterone and estrogen deficiency. Subjects consumed an ad libitum diet. Morning fasting blood and urine samples were collected to measure serum phosphate, serum intact FGF-23, PTH, and the maximum tubular reabsorption of phosphate (T(m)P/GFR) at baseline, weeks 4 and 12. The changes in serum FGF-23 and phosphate at weeks 4 and 12 were compared to baseline using paired t-tests. RESULTS: Goserelin therapy decreased mean serum testosterone levels from 543+/-160 ng/dL to 33+/-15 ng/dL at week 4 (p<0.001), and to 20+/-10 ng/dL at week 12 (p<0.001). Serum phosphate increased significantly from 3.4+/-0.6 mg/dL to 3.9+/-0.4 mg/dL at week 4 (p=0.002), and to 4.3+/-0.4 mg/dL at week 12 (p<0.001). T(m)P/GFR increased significantly from 3.2+/-0.6 mg/dL to 3.6+/-0.5 mg/dL at week 4 (p<0.004), and to 4.1+/-0.6 mg/dL at week 12 (p<0.001). FGF-23 levels, however, did not change during the 12-week study. CONCLUSIONS: Gonadal steroid deprivation increased serum phosphate levels in men but did not affect serum FGF-23 concentrations. The absence of any change in circulating FGF-23 suggests that supraphysiologic levels of serum phosphate may be required to stimulate circulating FGF-23 or that FGF-23 production is primarily sensitive to changes in dietary phosphate or 1,25 dihydroxyvitamin D within this physiologic serum phosphate range.
INTRODUCTION: Fibroblast growth factor (FGF-23) is a novel phosphaturic factor. Current data suggest that serum phosphate, dietary phosphate and 1,25 dihydroxyvitamin D regulate circulating FGF-23 levels in vivo. We examined if hypogonadism-induced increases in serum phosphate are associated with increases in circulating FGF-23 in healthy men in the absence of dietary manipulation. MATERIALS AND METHODS: 25 healthy men were administered goserelin acetate (GnRH analog) 3.6 mg subcutaneously every 4 weeks for 12 weeks to induce acute testosterone and estrogen deficiency. Subjects consumed an ad libitum diet. Morning fasting blood and urine samples were collected to measure serum phosphate, serum intact FGF-23, PTH, and the maximum tubular reabsorption of phosphate (T(m)P/GFR) at baseline, weeks 4 and 12. The changes in serum FGF-23 and phosphate at weeks 4 and 12 were compared to baseline using paired t-tests. RESULTS: Goserelin therapy decreased mean serum testosterone levels from 543+/-160 ng/dL to 33+/-15 ng/dL at week 4 (p<0.001), and to 20+/-10 ng/dL at week 12 (p<0.001). Serum phosphate increased significantly from 3.4+/-0.6 mg/dL to 3.9+/-0.4 mg/dL at week 4 (p=0.002), and to 4.3+/-0.4 mg/dL at week 12 (p<0.001). T(m)P/GFR increased significantly from 3.2+/-0.6 mg/dL to 3.6+/-0.5 mg/dL at week 4 (p<0.004), and to 4.1+/-0.6 mg/dL at week 12 (p<0.001). FGF-23 levels, however, did not change during the 12-week study. CONCLUSIONS: Gonadal steroid deprivation increased serum phosphate levels in men but did not affect serum FGF-23 concentrations. The absence of any change in circulating FGF-23 suggests that supraphysiologic levels of serum phosphate may be required to stimulate circulating FGF-23 or that FGF-23 production is primarily sensitive to changes in dietary phosphate or 1,25 dihydroxyvitamin D within this physiologic serum phosphate range.
Authors: K E White; K B Jonsson; G Carn; G Hampson; T D Spector; M Mannstadt; B Lorenz-Depiereux; A Miyauchi; I M Yang; O Ljunggren; T Meitinger; T M Strom; H Jüppner; M J Econs Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: C Wang; R S Swerdloff; A Iranmanesh; A Dobs; P J Snyder; G Cunningham; A M Matsumoto; T Weber; N Berman Journal: Clin Endocrinol (Oxf) Date: 2001-06 Impact factor: 3.478
Authors: T Shimada; S Mizutani; T Muto; T Yoneya; R Hino; S Takeda; Y Takeuchi; T Fujita; S Fukumoto; T Yamashita Journal: Proc Natl Acad Sci U S A Date: 2001-05-08 Impact factor: 11.205
Authors: Suzanne M Jan De Beur; Richard B Finnegan; John Vassiliadis; Brian Cook; Dana Barberio; Scott Estes; Partha Manavalan; Joseph Petroziello; Stephen L Madden; Justin Y Cho; Rajiv Kumar; Michael A Levine; Susan C Schiavi Journal: J Bone Miner Res Date: 2002-06 Impact factor: 6.741
Authors: Benjamin Z Leder; Karen M LeBlanc; David A Schoenfeld; Richard Eastell; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2003-01 Impact factor: 5.958
Authors: Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix Journal: Kidney Int Date: 2010-06-09 Impact factor: 10.612
Authors: W Wulaningsih; M Van Hemelrijck; K Michaelsson; N Kanarek; W G Nelson; J H Ix; E A Platz; S Rohrmann Journal: Andrology Date: 2014-10-01 Impact factor: 3.842
Authors: Peter C Chang; Sharmeela Saha; Amanda M Gomes; Aparna Padiyar; Kenneth A Bodziak; Emilio D Poggio; Donald E Hricik; Joshua J Augustine Journal: Clin J Am Soc Nephrol Date: 2011-02-10 Impact factor: 8.237
Authors: Sherri-Ann M Burnett-Bowie; Maria P Henao; Melissa E Dere; Hang Lee; Benjamin Z Leder Journal: J Bone Miner Res Date: 2009-10 Impact factor: 6.741